Dalamagkas Kyriakos, Tsintou Magdalini, Seifalian Alexander M
Department of Tissue Engineering, Harvard Medical School, Boston, MA, USA; Nanotechnology & Regenerative Medicine Centre, Division of Surgery and Interventional Science, University College London, London, UK.
Nanotechnology & Regenerative Medicine Commercialisation Centre (Ltd.), The London BioScience Innovation Centre, London, UK.
Neural Regen Res. 2018 Jan;13(1):35-42. doi: 10.4103/1673-5374.224360.
Spinal cord injury (SCI) is a highly debilitating neurological disease, which still lacks effective treatment strategies, causing significant financial burden and distress to the affected families. Nevertheless, nanotechnology and regenerative medicine strategies holding promise for the development of novel therapies that would reach from bench to bedside to serve the SCI patients. There has already been significant progress in the field of cell-based therapies, with the clinical application for SCI, currently in phase II of the clinical trial. Stem cells (e.g., induced pluripotent stem cells, fetal stem cells, human embryonic stem cells, and olfactory ensheathing cells) are certainly not to be considered the panacea for neural repair but, especially when combined with rehabilitation or other combinatorial approaches using the help of nanotechnology, they seem to be the source of some of the most promising and clinical translatable cell-based therapies that could help solving impactful problems on neural repair.
脊髓损伤（SCI）是一种极具致残性的神经疾病，目前仍缺乏有效的治疗策略，给受影响家庭带来了巨大的经济负担和痛苦。然而，纳米技术和再生医学策略有望开发出从实验室到临床应用的新型疗法，为脊髓损伤患者提供帮助。基于细胞的疗法领域已经取得了重大进展，目前针对脊髓损伤的临床试验已进入二期阶段。干细胞（如诱导多能干细胞、胎儿干细胞、人类胚胎干细胞和嗅鞘细胞）当然不能被视为神经修复的万灵药，但特别是当与康复或借助纳米技术的其他联合方法相结合时，它们似乎是一些最有前景且可临床转化的基于细胞的疗法的来源，有望帮助解决神经修复方面的重大问题。
